Cancer Research Institute and Stand Up To Cancer Announce SU2C-CRI Cancer Immunology Translational Research Dream Team Program
Cancer Research Institute -- Mar. 7, 2012 -- CRI and SU2C will provide $6 million to a Dream Team focused on creating new immune system-based cancer treatments

Antibodies to Intracellular Cancer Antigens Combined with Chemotherapy Enhance Anti-Cancer Immunity
Cancer Research Institute & Ludwig Institute for Cancer Research -- Feb. 13, 2012 -- Scientists successfully target antibodies to elusive intracellular cancer antigens, opening up vast new possible targets for cancer therapy.

DNA Sequencing Helps Idenfity Cancer Cells for Immune Attack
Washington University -- Feb. 8, 2012 -- DNA sequences from tumor cells can be used to direct the immune system to attack cancer, according to scientists at Washington University School of Medicine in St. Louis

Lloyd J. Old, M.D., "Father of Modern Tumor Immunology," Dies at 78 of Prostate Cancer
Cancer Research Institute – 11/28/11 – CRI founding scientific and medical director Lloyd J. Old, M.D., loses battle with prostate cancer at age 78. 

Cancer Immunotherapy Consortium Appoints New Leadership
Cancer Research Institute – 11/09/11 – The leading international association of cancer immunotherapy developers and research scientists has named two new directors to oversee the program's efforts to bring effective cancer immunotherapies to patients sooner.

25th Annual CRI Awards Dinner Honors Oustanding Contributions to Cancer Immunotherapy
Cancer Research Institute – 10/21/11 – Hollywood producer Laura Ziskin, Dendreon CEO Mitchell Gold, among honorees at annual CRI gala. 

Three Cancer Research Institute Scientists to Receive the 2011 Nobel Prize
Cancer Research Institute – 10/04/11 – Three immunologists will receive the 2011 Nobel Prize in Physiology or Medicine.

Cancer Vaccine Collaborative Appoints New Director, Expands Leadership
Cancer Research Institute and Ludwig Institute for Cancer Research – 9/22/11 – Jedd D. Wolchok, M.D., Ph.D., has been named director of the Cancer Vaccine Collaborative, which has also expanded its leadership to include seven new cancer immunotherapy experts.

Cancer Research Institute to Honor Former Postdoctoral Fellow at 25th Annual Awards Dinner
Cancer Research Institute – 9/08/11 – Stephen C. Jameson, Ph.D., will receive the 2011 Frederick W. Alt Award for New Discoveries in Immunology at CRI's 25th annual awards gala on October 3, 2011, in New York City.

Cancer Research Institute to Honor Pioneers in Adoptive Immunotherapy
Cancer Research Institute – 9/01/11 – Philip D. Greenberg, M.D., and Steven A. Rosenberg, M.D., Ph.D., will jointly receive the 2011 William B. Coley Award at CRI annual gala on October 3, 2011.

Mitchell H. Gold, CEO of Dendreon Corporation, to Receive 2011 Oliver R. Grace Award
Cancer Research Institute – 8/17/11 – Maker of the first FDA-approved therapeutic cancer vaccine to be honored at fall gala in New York City. 

Regulatory T Cell Stifles Antibody Production Centers
MD Anderson – 7/25/11 – A CRI investigator at MD Anderson Cancer Center and colleagues have identified the role of a regulatory T cell in the inhibition of antibody production.

Cancer Research Institute Announces New Programs
Cancer Research Institute – 7/25/11 – Nonprofit organization launches new programs to accelerate the discovery and development of safe and effective immune system-based treatments for cancer patients 

CRI Awards $9.7 Million in Grants to Support Immunology and Tumor Immunology Research
Cancer Research Institute – 7/6/11 – Newly announced research grants will help advance the next wave in cancer treatment.

Enlisting the Body to Fight Cancer
Wall Street Journal – 6/14/11 – Scientists are developing medications that fight cancer by spurring the body's immune system. 

Hollywood Producer and Cancer Activist Laura Ziskin Dies of Breast Cancer
Cancer Research Institute – 6/13/11 – 2011 Oliver R. Grace Award honoree Laura Ziskin, a powerful Hollywood producer and co-founder of Stand Up to Cancer, dies of breast cancer. 

First-Line Ipilimumab, an Immunotherapy, Also Improves Overall Survival
Medscape Today – 6/6/11 – The immunotherapy ipilimumab (Yervoy) is effective at first-line therapy in melanoma, increasing the number of patients who can benefit from the drug, which has just been approved for use as a second-line therapy. 

Therapeutic Melanoma Vaccine Improves Response Rate, Progression-Free Survival
MD Anderson Cancer Center – 6/1/11 – A vaccine for one of the most lethal cancers, advanced melanoma, has improved patient response rate and progression-free survival when combined with the immunotherapy drug Interleukin-2. 

Scientists Develop Microchip for Immune Monitoring
Scicasts – 5/26/11 – A new microchip can analyze a single drop of a patient's blood to determine responses to immunotherapy like cancer vaccines. 

White Blood Cells May Predict Mesothelioma Survival
Surviving Mesothelioma – 5/24/11 – Certain types of immune cells may hold important survival clues for mesothelioma patients, and may provide new targets for cancer immunotherapy.

Cancer-Fighting Cells Get Memory Boost
CBC News – 4/27/11 – Scientists in a CRI-funded study show that combining a cancer vaccine with ipilimumab helps patients' immune cells fight deadly melanoma longer than with vaccine alone.

"Through the Kitchen" Benefit for Cancer Research Institute
Wall Street Journal – 4/20/11 – A tribute notable New Yorkers held at the Four Seasons Restaurant in New York City raised more than $685,000 for the Cancer Research Institute postdoctoral fellowship program.

New Perspectives on Cancer and the Immune System
Cancer Research Institute – 3/25/11 – Today's announcement of the FDA's approval of Yervoy (ipilimumab) to treat metastatic melanoma represents a new milestone for the field of tumor immunology. Three CRI scientists review the field's progress over the past forty years, and lay out the challenges that lie ahead.

FDA Approves Ipilimumab, an Immunotherapy, for Metastatic Melanoma
Cancer Research Institute – 3/25/11 – The U.S. Food and Drug Administration announced today its approval of Yervoy (ipilimumab), a monoclonal antibody discovered by CRI scientist James P. Allison, to treat advanced melanoma.

Advaxis approved to complete dosing in phase II cervical cancer vaccine trial
Genetic Engineering & Biotechnology News – 1/14/11 – Advaxis has been approved to finish dosing of its cervical cancer vaccine ADXS11-01, developed by CRI-funded researchers Yvonne Paterson, Ph.D., and Reshma Singh, Ph.D.

CRI scientists named prestigious Fellows of the American Association for the Advancement of Science
American Association for the Advancement of Science – 1/11/11 – CRI scientists Frederick Alt, Jason Cyster, Jorge Galan, and Mien-Chie Hung among those elected as Fellows.

Lung cancer vaccine registered in Peru
Living in Peru – 1/10/11 – Cuban scientists report registering the lung cancer vaccine CIMAVAX-EGF in Peru.

New discovery by former CRI fellow Mien-Chie Hung, Ph.D.
Newswise – 1/3/11 – Dr. Mien-Chie Hung, 1983-86 CRI Fellow, and colleagues have found that the protein CDK1 deactivates EZH2, which is overexpressed in many cancers.

Phase III clinical trial commenced for therapeutic vaccine for head and neck cancer
Genetic Engineering & Biotechnology News – 12/29/10 – Cel-Sci has commenced a pivotal phase III clinical study of its Multikine vaccine for head and neck cancer.

Immune system may impact tumor blood supply
American Association for Cancer Research – 12/15/10 – CRI researcher Glenn Dranoff and others report that experimental cancer vaccine induces antibody responses that target blood vessel formation.

Breast inflammation is key to cancer growth, researchers say
EurekAlert – 12/15/10 – For the first time, scientists prove that inflammation in the breast is key to the development and progression of breast cancer.

CRI announces launch of Cancer Vaccine Acceleration Fund
Cancer Research Institute – 12/14/10 – An innovative model of "venture philanthropy" speeds development of highly promising cancer immunotherapies.

Tolerx and Cancer Research Institute collaborate on promising new immunotherapy
PR Newswire – 12/01/10 – TRX518, a first-in-class anti-GITR monoclonal antibody from biopharmaceutical company Tolerx, will be tested as a monotherapy for patients with advanced melanoma within the CRI/LICR Cancer Vaccine Collaborative